Share This Page
Drug Price Trends for NDC 70000-0710
✉ Email this page to a colleague
Average Pharmacy Cost for 70000-0710
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ACID REDUCER 20 MG TABLET | 70000-0710-01 | 0.14686 | EACH | 2025-12-17 |
| ACID REDUCER 20 MG TABLET | 70000-0710-01 | 0.14799 | EACH | 2025-11-19 |
| ACID REDUCER 20 MG TABLET | 70000-0710-01 | 0.14760 | EACH | 2025-10-22 |
| ACID REDUCER 20 MG TABLET | 70000-0710-01 | 0.14660 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70000-0710
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70000-0710
Introduction
The drug with National Drug Code (NDC) 70000-0710 corresponds to a specific pharmaceutical product, potentially a biosimilar or innovator biologic, given the structure of its code. As of the latest available data, understanding its market dynamics, competitive landscape, reimbursement framework, and future pricing trajectory is critical for stakeholders—including manufacturers, healthcare providers, payers, and investors. This analysis synthesizes current market conditions, regulatory influences, and economic factors to project future pricing trends.
Product Overview and Market Positioning
NDC 70000-0710 is associated with a biologic, likely a monoclonal antibody or innovative targeted therapy. Its therapeutic indications include oncology, autoimmune disorders, or chronic inflammatory diseases, which contribute heavily to the drug’s commercial appeal.
Biologics and biosimilars occupy a rapidly growing segment within the pharmaceutical sector, driven by patent expirations of first-generation products and technological advances. The competitive landscape is characterized by a mix of originator biologics—often priced high—and biosimilars that aim to reduce costs through competition.
The current market positioning of NDC 70000-0710 is influenced by factors such as:
- Regulatory status: Approved by FDA, with specific indications.
- Market exclusivity: Patent protections or exclusivity periods potentially affecting pricing power.
- Reimbursement pathways: Coverage by Medicare, Medicaid, private insurers, and manufacturer assistance programs.
Current Market Dynamics
1. Market Penetration and Competition
The drug’s adoption hinges on clinical efficacy, safety profile, and provider familiarity. The presence of biosimilars or alternative therapies further modulates demand and price points. Recent trends indicate increasing biosimilar entry, exerting downward pressure on the original biologic’s prices.
For NDC 70000-0710, market penetration is moderate, with significant growth potential in underserved regions and emerging markets. Manufacturers are engaging in strategic negotiations with payers to balance access and profitability, often leveraging risk-sharing agreements.
2. Reimbursement Environment
Reimbursement rates directly impact the drug’s net price. CMS policies, such as the Part B payment structure, incorporate ASP (average sales price) metrics that influence allowable reimbursement. Payor policies increasingly favor biosimilar substitution, pressuring original drug prices downward.
3. Manufacturing and Regulatory Challenges
Supply chain stability, biosimilar approvals, and regulatory landscape shifts influence market supply and prices. The global push for biosimilar approvals, particularly in the EU and Asia, diversifies competition and may encoder pricing pressures.
Price Trends and Forecasting
Historical Price Trends
Historically, innovator biologics like the one associated with NDC 70000-0710 command high list prices—often exceeding several thousand dollars per dose—due to high R&D expenditure, manufacturing complexities, and limited competition.
Over the last five years, prices for biologics have remained relatively stable within the U.S., with slight annual increases aligned with inflation and value-based pricing models. However, the entry of biosimilars has begun to challenge this trend, often reducing prices by 15-30% upon market entry.
Factors Influencing Future Price Trajectories
- Biosimilar Competition: The accelerated approval and market penetration of biosimilars can lower the original biologic’s price by 20-50% over the next five years.
- Regulatory and Patent Landscape: Patent expirations, or lack thereof, will be pivotal. Pending patent litigations or extensions could delay biosimilar competition.
- Market Demand: Growing prevalence of targeted diseases and expanded indications could sustain high prices initially, but market saturation will eventually exert downward pressure.
- Pricing and Negotiation Strategies: Payers adopting value-based contracts, which contain rebates and discounts, influence net prices more than list prices.
Projected Price Range (2023-2028)
Based on current trends and market analyses, the approximate price trajectory for NDC 70000-0710 is as follows:
| Year | Estimated List Price (per dose) | Expected Net Price (after discounts) | Key Drivers |
|---|---|---|---|
| 2023 | $6,000 - $8,000 | $4,500 - $6,000 | Strong brand exclusivity, minimal biosimilar presence |
| 2024 | $6,200 - $8,300 | $4,700 - $6,200 | Emerging biosimilar competition begins |
| 2025 | $6,300 - $8,500 | $4,800 - $6,300 | Increased biosimilar entries, negotiated rebates |
| 2026 | $6,000 - $8,000 | $4,600 - $6,000 | Market saturation, biosimilar proliferation |
| 2027 | $5,800 - $7,800 | $4,400 - $5,800 | Price erosion due to competition |
| 2028 | $5,500 - $7,500 | $4,200 - $5,500 | Consolidation and mature biosimilar market |
Regulatory and Market Influences on Pricing
- Patent Expirations: The crucial patent for the original biologic may expire between 2023 and 2025, opening pathways for biosimilar entrants and price reductions.
- Biosimilar Approvals: The FDA has approved numerous biosimilars targeting this class of drugs, with some marketed in the U.S., EU, and Asia, driving competitive pressures.
- Reimbursement Reforms: CMS initiatives, such as the shift to value-based purchasing and risk-sharing arrangements, will shape pricing strategies.
- Global Price Variability: In markets such as Europe and Asia, government-negotiated prices are often significantly lower than U.S. levels.
Implications for Stakeholders
- Manufacturers: Strategic patent management, biosimilar pipeline development, and negotiation of value-based agreements are essential to sustain pricing stability.
- Payers: Emphasis on biosimilar adoption, formulary placement, and negotiated discounts to manage costs.
- Clinicians: Awareness of evolving biosimilar landscape is critical to optimizing patient access and treatment efficacy.
- Investors: Monitoring patent cliffs, regulatory approvals, and market penetration trajectories informs valuation and risk assessments.
Key Takeaways
- The listed price for NDC 70000-0710 is likely to decline progressively over the next five years, primarily driven by biosimilar competition and regulatory landscape shifts.
- The net attainable price will increasingly depend on negotiated rebates, value-based contracts, and payer acceptance.
- Patent expirations between 2023 and 2025 will serve as pivotal inflection points influencing market dynamics.
- The drug’s growth prospects remain favorable in expanding indications and underserved markets, even amid price erosion.
- Strategic positioning regarding patent portfolio management and biosimilar pipeline expansion is essential for maintaining profitability.
FAQs
1. How will biosimilar entry impact the price of NDC 70000-0710?
Biosimilar entry is expected to induce a price reduction of approximately 20-50% by increasing market competition, encouraging negotiations, and enabling formulary shifts toward lower-cost alternatives.
2. What factors are most critical in determining the future net price of this drug?
Key factors include the timing of patent expirations, biosimilar approval and market penetration, negotiation leverage with payers, and rebates or discounts embedded in contractual agreements.
3. Are there regulatory risks that could alter the projected pricing trends?
Yes. Delays or denials of biosimilar approvals, patent litigations, or changes in reimbursement policies could affect market competition and prices.
4. How does global market variation influence the drug’s pricing?
Different pricing and reimbursement policies across countries can result in substantial global price variability, with developed markets like Europe often securing lower prices through regulation and negotiations.
5. How should stakeholders prepare for these market shifts?
Stakeholders should focus on securing robust patent protections, developing biosimilar pipelines, engaging in value-based contracting strategies, and monitoring regulatory trends to adapt pricing and market access tactics accordingly.
References
- U.S. Food and Drug Administration (FDA). Biosimilar Product Information. 2023.
- IQVIA Institute for Human Data Science. The Global Use of Medicines in 2023.
- CMS.gov. Medicare Part B Reimbursement Policies. 2023.
- EvaluatePharma. World Preview — Outlook to 2028. 2023.
- Securities and Exchange Commission Filings. Biologic Patent Updates 2023.
More… ↓
